Prolia drug class?

What class of drug is Prolia?

Prolia (denosumab) is a prescription monoclonal antibody that belongs to the antiresorptive class of osteoporosis medicines. It works by blocking RANKL (receptor activator of nuclear factor kappa-B ligand), which reduces bone breakdown.

Is Prolia an antiresorptive or an anabolic osteoporosis drug?

Prolia is an antiresorptive drug, not an anabolic therapy. Anti-resorptives slow or inhibit bone resorption (bone breakdown), while anabolic drugs stimulate new bone formation.

What does Prolia target in the body (RANKL)?

Prolia binds to RANKL, preventing it from activating its receptor pathway involved in osteoclast formation and activity. This lowers osteoclast-driven bone resorption and helps increase or maintain bone mineral density.

How does Prolia compare with bisphosphonates (common osteoporosis alternatives)?

Prolia is not a bisphosphonate. Bisphosphonates directly inhibit osteoclast activity and are typically taken orally or via infusion, whereas Prolia is an injection (subcutaneous) that works by neutralizing RANKL.

Where to check patents and brand/generic information for Prolia?

DrugPatentWatch.com tracks patent and exclusivity information for branded medicines and can help if you’re researching Prolia’s IP landscape. You can start here: https://www.drugpatentwatch.com/